Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder

Pharmacotherapy

Volumn 30, Issue 9, 2010, Pages 942-951

  Lorenz, Raymond A ^a,b   Jackson, Cherry W ^a   Saitz, Marianne ^b,c  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c AltaPointe Health Systems   (United States)

Author keywords

Atypical antipsychotics; Generalized anxiety disorder; Treatment resistance

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRIFLUOPERAZINE; VENLAFAXINE; ZIPRASIDONE;

ANTEROGRADE AMNESIA; ANXIETY DISORDER; APPETITE; BLURRED VISION; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE THERAPY; CONCENTRATION LOSS; DIARRHEA; DIZZINESS; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; HYPERGLYCEMIA; INSOMNIA; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PANIC; RESTLESSNESS; REVIEW; RIGIDITY; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; DIBENZOTHIAZEPINES; DRUG RESISTANCE; HUMANS; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS; THIAZOLES;

EID: 77956155318     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.9.942     Document Type: Review

References (51)

1. Wittchen HU, Hoyer J. Generalized anxiety disorder: nature and course. J Clin Psychiatry 2001;62(suppl 11):15-19.
2. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age of onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62:593-602. (Pubitemid 40973434)
3. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, comorbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the national epidemiologic survey on alcohol and related conditions. Psychol Med 2005;35:747-59.
4. Wittchen HU, Zhao S, Kessler RC, et al. DSM III-R generalized anxiety disorder in the national comorbidity survey. Arch Gen Psychiatry 1994;51:355-64. (Pubitemid 24176813)
5. Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the national comorbidity study (NCS). Acta Psychiatr Scand 1998;98(suppl 393):6-11.
6. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16:162-71.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition-text revised. Washington, DC: American Psychiatric Association; 2000.
8. Boden JM, Fergusson DM, Horwood LJ. Anxiety disorders and suicidal behaviors in adolescence and young adulthood: findings from a longitudinal study. Psycholo Med 2007;37:431-40.
9. Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry 2001;62(suppl 11):37-42.
10. Fisher PL, Durham RC. Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990. Psychol Med 1999;29:1425-34.
11. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988;49:293-301.
12. Montgomery SA, Sheehad DV, Meoni P, et al. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long term treatment with venlafaxine XR. J. Psych Res 2002;36:209-17.
13. Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2008;18:673-81.
14. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment . Int J Neuropsychopharmacol 2006;9:495-505.
15. Pollack HH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible dosage trial. J Clin Psychiatry 2001;62:350-7.
16. Browning M, Reid C, Cowen PJ, et al. A single dose of citalopram increased fear recognition in healthy subjects. J Psychopharmacol 2007;21:684-90. (Pubitemid 47437913)
17. Soumerai SB, Simoni-Wastila L, Singer C, et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv 2003;54:1006-11.
18. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1991;105:428-32.
19. Rickels K, Wiseman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982;43:81-6.
20. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabaline and alprazolam. Arch Gen Psychiatry 2005;62:1022-30.
21. Montgomery SA. Pregabalin for the treatment of generalized anxiety disorder. Expert Opin Pharmacother 2006;7:2139-54.
22. Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalized anxiety disorder. Br J Psychiatry 1996;168:308-13.
23. Mendels J, Krajewski TF, Huffer V, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 1986;47:170-4. (Pubitemid 16109750)
24. Reynolds GP. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004;18:340-5.
25. Carson WH, Kitagawa H. Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol Bull 2004;38:38-45.
26. 1A agonist and a 5-HT2C antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacology (Berl) 2003;167:344-52.
27. Llorca PM, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 2002;63:1020-7.
28. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88.
29. Hirschfeld RM, Weisler RH, Raines SR, et al, for the BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006;67:355-62.
30. Worthington JJ III, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20:9-11. (Pubitemid 40105542)
31. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 2005;86:99-104.
32. Menza MA, Dobkin RD, Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol 2007;27:207-10.
33. Hoge EA, Worthington JJ III, Kaufman RE, et al. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr 2008;13:522-7.
34. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006;59:211-15.
35. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007;24:487-94.
36. Simon NM, Connor KM, LeBeau RT, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl) 2008;197:675-81.
37. Katzman MA, Vermani M, Jacobs L, et al. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 2008;22:1480-6.
38. Simon NM, Hoge EA, Fischmann D, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 2006;67:381-5.
39. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005;66:1321-5.
40. Pandina GJ, Canuso CM, Turkoz I, et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull 2007;40:41-57.
41. Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol 2005;25:497-9. (Pubitemid 41368377)
42. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 2004;9(suppl 11):6-14.
43. Akimova E, Lanzenberger R, Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 2009;66:627-35.
44. AstraZeneca Pharmaceuticals. Quetiapine (seroquel XR) product information. Wilmington, DE; 2009.
45. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2006;67:1741-6.
46. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
47. Joyce M, Khan A, Atkinson S, et al. Efficacy and safety of extended release quetiapine fumarate in patients with generalized anxiety disorder [abstract NR3138]. Presented at the 161st annual meeting of the American Psychiatric Association, Washington, DC, May 3-8, 2008.
48. Merideth C, Cutler A, Neijber A, et al. Efficacy and safety of extended release quetiapine fumarate in patients with generalized anxiety disorder. Presented at the 21st congress of the European College of Neuropsychopharmacology, Barcelona, Spain, August 30-September 3, 2008.
49. Bandelow B, Bobes J, Ahokas A, et al. Results from a phase 3 study of once daily extended release quetiapine fumarate monotherapy in patients with generalized anxiety disorder. Presented at the 7th international forum on mood and anxiety disorders, Budapest, Hungary, December 5-7, 2007.
50. Katzman M, Brawman-Mintzer O, Reyes E, et al. Extended release quetiapine fumarate monotherapy in maintenance treatment of generalized anxiety disorder: efficacy and tolerability results from a randomized, placebo-controlled trial [abstract: NR 3140]. Presented at the 161st annual meeting of the American Psychiatric Association, Washington, DC, May 3-8, 2008.
51. U.S. Food and Drug Administration. Minutes for the April 8, 2009 meeting of the psychopharmacologic drugs advisory committee. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM198219.pdf. Accessed March 4, 2010.